In a surprising twist, Neximmune Inc (NEXI) has shown an exceptional performance during the pre-market hours today, creating ripples in the financial realm. The stock experienced a remarkable surge of 208.21%, or $4.95 in this early trading session. Notably, the trading volume in the pre-market soared to a substantial 8.31 million shares, signaling a surge in investor engagement and increased market dynamics.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The substantial shift in Neximmune’s pre-market activity sparks curiosity, prompting a closer look at the underlying factors behind this impressive stock value change. Market participants are closely monitoring the consequences of this significant pre-market upswing as the trading day unfolds.
Latest News
On October 24, 2023, NexImmune, Inc. (Nasdaq: NEXI) disclosed the expansion of the collaborative research initiative involving NexImmune, Yale, and JDRF, aimed at exploring the application of NexImmune’s AIM nanoparticles in conjunction with an anti-CD3 mAb to tolerize, deplete, or modulating diabetes antigen-specific T cells.
As part of the extension, JDRF has allocated an additional grant of $300,000 to Yale under its Cures research portfolio, focusing on therapies for type 1 diabetes (T1D) prevention.
The JDRF grant will continue supporting investigations into using NexImmune’s AIM nanoparticles in combination with a murine surrogate of teplizumab, known to modulate the pathogenic immune response acutely.
The integration of anti-CD3 treatment with NexImmune’s injectable therapy presents an opportunity to specifically target and modulate T1D antigen-specific T cells, potentially sustaining their non-responsiveness to extend benefits and induce tolerance. The unique properties of NexImmune’s nanoparticles offer the potential to further amplify the impact of anti-CD3 by influencing the residual T1D-specific T cells.
